Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

HALO is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 11.4X for the current fiscal year compared to the Medical – Biomedical and Genetics industry’s P/E of 22.3X. Additionally, HALO has a PEG Ratio of 0.4 and a Price/Cash Flow ratio of 17.8X. Value investors should also note HALO’s Price/Sales ratio of 7.6X.

Value investors don’t just pay attention to a company’s valuation ratios; positive earnings play a crucial role, too. One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.02 to $4.13 per share. HALO has an average earnings surprise of 14.9%.

Source: FINANCE.YAHOO